Cosmos Health appoints AI drug discovery expert to advisory board

Cosmos Health Inc. (NASDAQ: COSM) appointed Dr. Dimitrios Iliopoulos to its advisory board to support the company's biotechnology initiatives focused on AI-driven drug discovery and clinical-stage therapeutic development, according to a company statement.

Dr. Iliopoulos serves as co-founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company developing precision therapeutics for autoimmune diseases. Athos developed AthosOmics.AI, a proprietary AI-driven drug development platform that led to the discovery of ATH-063, an AI-derived small molecule currently in Phase 2 clinical trials for ulcerative colitis patients.

The appointee previously held academic positions at Harvard Medical School as an assistant professor of microbiology and immunology, and later became a tenured associate professor of medicine at UCLA School of Medicine. At UCLA, he founded and directed the UCLA Center for Systems Biomedicine, which received funding from the Eli & Edythe Broad Foundation.

Dr. Iliopoulos has published more than 130 peer-reviewed scientific articles in biomedical journals with over 24,000 citations. He has received awards from institutions including the National Institutes of Health, the American Association for Cancer Research, the Sidney Kimmel Foundation, and the Leona & Harry Helmsley Foundation.

His research work at Harvard demonstrated that metformin, an anti-diabetic drug, possesses anti-cancer properties, leading to multiple cancer clinical trials. At UCLA, his team identified miR-124 as an anti-inflammatory drug target for ulcerative colitis.

Dr. Iliopoulos holds an MBA and finance certification from UCLA Anderson School of Management and Stanford Graduate School of Business. He co-authored "Biotechnology Valuation & Investing (2nd Edition)" and developed a real-options financial framework for valuing early-stage biotechnology products and companies.

Cosmos Health operates as a diversified, vertically integrated global healthcare group with a portfolio of pharmaceutical and nutraceutical brands.

You May Also Be Interested In

• Cosmos Health signs Saudi distribution deal for supplement line
• EShallGo closes $1.75M registered direct offering at $1 per share
• VirTra wins $1.5M Army contract for firearms training in Tajikistan